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Abstract. 
 
Plasminogen activator inhibitor 1 (PAI-1) is
a major inhibitor of urokinase-type plasminogen activa-
tor (uPA). In this study, we explored the role of PAI-1
in cell signaling. In MCF-7 cells, PAI-1 did not directly
activate the mitogen-activated protein (MAP) kinases,
extracellular signal–regulated kinase (ERK) 1 and
ERK2, but instead altered the response to uPA so
that ERK phosphorylation was sustained. This effect
required the cooperative function of uPAR and the
very low density lipoprotein receptor (VLDLr). When
MCF-7 cells were treated with uPA–PAI-1 complex in
the presence of the VLDLr antagonist, receptor-associ-
 
ated protein, or with uPA–PAI-1
 
R76E
 
 complex, which
binds to the VLDLr with greatly decreased afﬁnity,
transient ERK phosphorylation (
 
,
 
5 min) was ob-
served, mimicking the uPA response. ERK phosphory-
lation was not induced by tissue-type plasminogen acti-
vator–PAI-1 complex or by uPA–PAI-1 complex in the
presence of antibodies that block uPA binding to
 
uPAR. uPA–PAI-1 complex induced tyrosine phosphor-
ylation of focal adhesion kinase and Shc and sustained
association of Sos with Shc, whereas uPA caused tran-
sient association of Sos with Shc.
By sustaining ERK phosphorylation, PAI-1 con-
verted uPA into an MCF-7 cell mitogen. This activity
was blocked by receptor-associated protein and not ob-
served with uPA–PAI-1
 
R76E
 
 complex, demonstrating
the importance of the VLDLr. uPA promoted the
growth of other cells in which ERK phosphorylation
was sustained, including 
 
b
 
3 integrin overexpressing
MCF-7 cells and HT 1080 cells. The MEK inhibitor,
PD098059, blocked the growth-promoting activity of
uPA and uPA–PAI-1 complex in these cells. Our results
demonstrate that PAI-1 may regulate uPA-initiated cell
signaling by a mechanism that requires VLDLr recruit-
ment. The kinetics of ERK phosphorylation in response
to uPAR ligation determine the function of uPA and
uPA–PAI-1 complex as growth promoters.
Key words: urokinase-type plasminogen activator •
plasminogen activator inhibitor 1 • urokinase receptor •
VLDL receptor • extracellular signal–regulated kinase
 
Introduction
 
Urokinase-type plasminogen activator (uPA)
 
1 
 
is a serine pro-
teinase that binds with high affinity to the glycosylphosphati-
dylinositol-anchored receptor, uPAR, and activates a cascade
of extracellular proteinases that includes plasmin and matrix
metalloproteinases (Mignatti and Rifkin, 2000). These acti-
vated proteinases degrade extracellular matrix proteins in
basement membranes and other tissue boundaries, facilitat-
ing cellular migration in vivo. Polarization of uPAR to the
leading edge of the migrating cell may optimally localize pro-
teinase activity (Estreicher et al., 1990; Gyetko et al., 1994).
Not surprisingly, uPA has been implicated in diverse pro-
cesses that require cellular migration, including inflamma-
tion, neointima formation, healing of myocardial infarcts,
cancer invasion, and metastasis (Carmeliet et al., 1994; Gy-
etko et al., 1996; Shapiro et al., 1996, 1997; Kim et al., 1998;
Lijnen et al., 1998; Heymans et al., 1999). However, not all of
the activities demonstrated by uPA in vivo may be attributed
to the function of uPA as a proteinase (Waltz et al., 2000).
Plasminogen activator inhibitor 1 (PAI-1) is a member of
the Serpin gene family and a major inhibitor of uPA (Mig-
natti and Rifkin, 2000). PAI-1 reacts rapidly with free and
uPAR-associated uPA (Ellis et al., 1990). Thus, PAI-1 might
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be expected to inhibit cellular migration through tissues and
prevent cancer invasion (Mignatti and Rifkin, 2000). How-
ever, there is substantial evidence that PAI-1 may promote
cancer progression. Coexpression of PAI-1 with uPA is nec-
essary for optimal invasion of lung carcinoma cells through
Matrigel in vitro
 
 
 
(Liu et al., 1995). In at least one study, PAI-1
deficiency in mice inhibited cancer cell invasion and de-
creased cancer angiogenesis (Bajou et al., 1998). Further-
more, high PAI-1 levels have been correlated with cancer
progression in patients (Jänicke et al., 1991; Kuhn et al.,
1994; Nekarda et al., 1994; Costantini et al., 1996; Schmitt et
al., 1997; Knoop et al., 1998). Taken together, these results
suggest that PAI-1 may express activities in vivo that are
more complex than simple proteinase inhibition.
In its active conformation, PAI-1 binds directly to vi-
tronectin and blocks the binding sites for 
 
a
 
V
 
b
 
3
 
 and uPAR,
inhibiting cell adhesion to vitronectin and altering cell mi-
gration (Deng et al., 1996; Stefansson and Lawrence, 1996;
Waltz et al., 1997). PAI-1 also binds sequentially to uPAR-
associated uPA and then to receptors in the low density li-
poprotein (LDL) receptor family, including low density
lipoprotein receptor-related protein and the very low den-
sity lipoprotein receptor (VLDLr) (Conese et al., 1995;
Webb et al., 1999). In the resulting quaternary complex,
uPA–PAI-1 functions as a structural bridge so that uPAR
undergoes endocytosis with the constitutively recycling
LDL receptor homologues (Conese et al., 1995; Nykjær et
al., 1997; Webb et al., 1999). Thus, the function of PAI-1 in
vivo reflects diverse integrated activities, including regula-
tion of cell surface proteolysis, cell adhesion, and uPAR
catabolism.
A novel mechanism whereby PAI-1 may regulate cell
physiology regards its potential to impact on cell signaling.
Although there is no evidence that PAI-1 directly initiates
cell signaling or modulates the response to other agonists,
receptors for the uPA–PAI-1 complex, including uPAR
and LDL receptor homologues, have been implicated in
cell signaling (Trommsdorf et al., 1998; Blasi, 1999; Hies-
berger et al., 1999). Binding of uPA to uPAR activates
p56/p59
 
hck
 
 (Resnati et al., 1996; Konakova et al., 1998), the
JAK–STAT pathway (Koshelnick et al., 1997; Dumler et
al., 1998), focal adhesion kinase (FAK) (Tang et al., 1998;
Yebra et al., 1999, Nguyen et al., 2000), protein kinase C
 
e
 
(Busso et al., 1994), casein kinase 2 (Dumler et al., 1999),
and the mitogen-activated protein (MAP) kinases, extra-
cellular signal–regulated kinase (ERK) 1 and ERK2
(Kanse et al., 1997; Konakova et al., 1998; Nguyen et al.,
1998; Tang et al., 1998; Ghiso et al., 1999). Since uPAR is
glycosylphosphatidylinositol-anchored, uPA-initiated cell
signaling probably requires one or more adaptor proteins
with transmembrane domains (Chapman et al., 1999).
When MCF-7 breast cancer cells are treated with uPA,
ERK is activated, and this signaling event is necessary for
promoting cell migration (Nguyen et al., 1998, 1999). In-
terestingly, ERK activation in MCF-7 cells by uPA does
not promote cell growth. This result may reflect the fact
that ERK phosphorylation is highly transient in uPA-
treated MCF-7 cells with levels returning to baseline in 
 
,
 
5
min. In the present investigation, we explored the effects
of PAI-1 on the Ras–ERK signaling pathway in MCF-7
cells. Although PAI-1 did not signal directly, it modulated
the response to uPA so that ERK activation was sustained.
The mechanism involved bridging of two essential recep-
tors, uPAR and the VLDLr, by the uPA–PAI-1 complex.
 
As a consequence of sustained ERK activation, PAI-1
converted uPA into an MCF-7 cell mitogen. In the ab-
sence of PAI-1, uPA still functioned as a mitogen towards
cell lines that demonstrate sustained ERK phosphoryla-
tion in response to uPA, including HT 1080 fibrosarcoma
cells and 
 
b
 
3 integrin overexpressing MCF-7 cells. The abil-
ity of PAI-1 to function as a uPA response modifier at the
level of cell signaling represents a novel mechanism
whereby PAI-1 may affect cell physiology.
 
Materials and Methods
 
Reagents and Proteins
 
Two-chain uPA was provided by Drs. Jack Henkin and Andrew Mazar
(Abbott Laboratories, Abbott Park, IL) and inactivated with diisopropyl
fluorophosphate to form diisopropyl phospho (DIP)–uPA as described
previously (Nguyen et al
 
.
 
, 1998). PAI-1 was provided by Dr. Duane Day
(Molecular Innovations, Southfield, MI). PAI-1
 
R76E 
 
was provided by Dr.
Daniel Lawrence (American Red Cross, Rockville, MD). This mutant
form of PAI-1 binds to receptors in the LDL receptor family with greatly
decreased affinity (Stefansson et al., 1998). uPA-specific monoclonal anti-
body, which is directed against the amino-terminal fragment of uPA (No.
3471), and uPAR-specific antibody 399R were from American Diagnos-
tica. Both of these antibodies, at a concentration of 25 
 
m
 
g/ml, inhibited
specific binding of 
 
125
 
I-DIP–uPA to MCF-7 cells by 
 
.
 
95% as demon-
strated previously (Nguyen et al., 1999). The MEK inhibitor, PD098059,
and the myosin light chain kinase (MLCK) inhibitor, ML-7, were from
Calbiochem-Novabiochem. Phosphorylated ERK-specific antibody was
from Promega or Calbiochem-Novabiochem. The polyclonal antibody
that recognizes total ERK was from Zymed Laboratories. Phosphoty-
rosine-specific monoclonal antibody 4G10 was from Upstate Biotechnol-
ogy. Sos1-specific polyclonal antibody (C-23) was from Santa Cruz
Biotechnology, Inc. FLAG-specific monoclonal antibody was from Strat-
agene. Monoclonal anti-HA antibody 12CA5 was from Babco. Shc-spe-
cific polyclonal antibody was from Transduction Laboratories. Mono-
clonal antibody LM609, which is specific for 
 
a
 
V
 
b
 
3
 
, was from Chemicon
International. The expression construct that encodes glutathione-
 
S
 
-trans-
ferase (GST)–receptor-associated protein (RAP) was obtained from Dr.
Joachim Herz (University of Texas Southwestern Medical Center, Dallas,
TX). GST-RAP was expressed and purified as described previously
(Webb et al
 
.
 
, 1999).
The uPA–PAI-1 complex was prepared by reacting 0.25 
 
m
 
M two-chain
uPA with an equimolar concentration of PAI-1 for 10 min at 37
 
8
 
C. The ac-
tivity of uPA in the uPA–PAI-1 complex was decreased to undetectable
levels as determined by the rate of hydrolysis of L-pyroglutamyl-gly-
cyl-arginine-
 
p
 
-nitroanilide. Two-chain tissue-type plasminogen activator
(tPA) was purchased from American Diagnostica and reacted with PAI-1
using the strategy described for uPA.
 
Cell Culture and Transfection
 
Low passage MCF-7 cells were provided by Dr. Richard Santen (Univer-
sity of Virginia, Richmond, VA) and cultured in RPMI supplemented
with 10% FBS, 100 U/ml penicillin, and 100 
 
m
 
g/ml streptomycin. HT 1080
fibrosarcoma cells were obtained from the American Type Culture Col-
lection and cultured in MEM supplemented with 10% FBS, 100 U/ml pen-
icillin, and 100 
 
m
 
g/ml streptomycin. Cells were passaged at subconfluence
using enzyme-free cell dissociation buffer (Life Technologies) and main-
tained in culture for at least 48 h before performing experiments.
The full-length cDNA encoding the 
 
b
 
3 integrin was provided by Dr.
David Cheresh (Scripps Research Institute, La Jolla, CA) and subcloned
into pBK–CMV. This construct was linearized and transfected into MCF-7
cells using Superfect (QIAGEN). After selection in G418 (1 mg/ml) for
3 wk, cells were single-cell cloned by serial dilution. 
 
b
 
3 integrin expression
was confirmed by FACS
 
®
 
 analysis using antibody LM609 (Nguyen et al.,
1999). Two clones were selected for further study.
 
Analysis of ERK Activation
 
MCF-7 and HT 1080 cells were cultured in 60-mm dishes. When the cul-
tures were 80% confluent, the cells were incubated in serum-free medium
for 12 h and then treated with 5 nM uPA–PAI-1 complex, 5 nM DIP–uPA,
0.4 
 
m
 
M GST-RAP, or 10 ng/ml EGF for the indicated times. HT 1080 cells
were incubated with 10 nM DIP–uPA. To terminate an incubation, the 
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medium was aspirated and replaced with ice cold 20 mM sodium phos-
phate, 150 mM NaCl, pH 7.4 (PBS) containing 1 mg/ml sodium orthovan-
adate. The cultures were then extracted in 1.0% Nonidet P-40, 50 mM
Hepes, 100 mM NaCl, 2 mM EDTA, 1 
 
m
 
g/ml leupeptin, 2 
 
m
 
g/ml aprotinin,
0.4 mg/ml sodium orthovanadate, 0.4 mg/ml sodium fluoride, and 5 mg/ml
dithiothreitol, pH 7.4. Extracts were subjected to SDS-PAGE on 12%
slabs. Proteins were transferred to nitrocellulose membranes and probed
with antibodies that detect phosphorylated and total ERK.
 
Tyrosine Phosphorylation of FAK and Shc
 
Constructs encoding FLAG-tagged FAK and HA-tagged Shc were ob-
tained from Drs. J. Thomas Parsons and Kodi Ravichandran (University
of Virginia, Charlottesville, VA), respectively. The constructs were trans-
fected into MCF-7 cells (10 
 
m
 
g of DNA/2 
 
3 
 
10
 
6
 
 cells) using Superfect.
Transfected cultures were maintained in serum-containing medium for
36 h, serum starved for 4 h, and then stimulated with uPA–PAI-1 complex
(5 nM) for the indicated times. The medium was aspirated and replaced
with ice cold PBS containing 1 mg/ml sodium orthovanadate. The cells
were then extracted and the protein content in each extract determined.
FLAG-tagged FAK and HA-tagged Shc were isolated from equal
amounts of cellular protein by immunoprecipitation. The immunoprecipi-
tated proteins were subjected to SDS-PAGE and electrotransferred to ni-
trocellulose membranes. Tyrosine-phosphorylated FAK and Shc were de-
tected by immunoblot analysis. Total levels of FAK and Shc were also
determined.
 
Coimmunoprecipitation of Sos1 with Shc
 
MCF-7 cells that were 80% confluent were cultured in serum-free RPMI
for 12 h and then treated with 5 nM uPA–PAI-1 complex or vehicle at
37
 
8
 
C for the indicated times. Some cultures were pre-incubated with 0.4
 
m
 
M RAP for 15 min to neutralize the activity of the VLDLr and then
treated with uPA–PAI-1 complex. The cells were washed with ice cold
PBS containing 1 mg/ml sodium orthovanadate and extracted in 
 
N-
 
octyl
glucoside as described previously (Nguyen et al., 2000). Shc was isolated
by immunoprecipitation from equal amounts of cellular protein. The im-
munoprecipitates were subjected to SDS-PAGE in the presence of dithio-
threitol and electrotransferred to nitrocellulose. Sos1 was detected by im-
munoblot analysis using antibody C-23.
 
Cell Migration Assays
 
Cell migration was studied using tissue culture–treated 6.5-mm Transwell
chambers with 8.0 
 
m
 
m pore membranes (Costar). The bottom surface of
each membrane was coated with 20% FBS as described previously
(Nguyen et al., 1998). MCF-7 cells were dissociated from monolayer cul-
ture, washed with serum-free medium, and transferred to the top chamber
of each Transwell at a density of 10
 
6
 
 cells/ml (100 
 
m
 
l). uPA–PAI-1 com-
plex (1 nM), DIP–uPA (1 nM), or PAI-1 (1–500 nM) were preincubated
with the cells in suspension for 15 min and then added to both chambers.
The bottom chamber contained RPMI 
 
1
 
 10% FBS. Migration was al-
lowed to proceed for 6 h at 37
 
8
 
C. Nonmigrating cells were removed from
the top surface of each membrane using a cotton swab. The membranes
were then fixed and stained with Diff-Quik (Dade Diagnostics). Cells that
penetrated to the lower surface of each membrane were counted. We
demonstrated previously that MCF-7 cells migrate equivalently on serum-
or vitronectin-coated surfaces (Nguyen et al
 
.
 
, 1999) which is anticipated
since vitronectin serves as the major cell attachment and spreading factor
in serum (Hayman et al
 
.
 
, 1985). Single-chain uPA and DIP–uPA are
equally effective at promoting MCF-7 cell migration and the response is
not affected by proteinase inhibitors that are present in the FBS in the
lower chamber (Nguyen et al., 1998, 1999).
 
Cell Growth Experiments
 
DNA synthesis was assessed in MCF-7 cells by measuring [
 
3
 
H]thymidine
incorporation. MCF-7 cells were plated at a density of 2.5 
 
3
 
 10
 
4
 
 cells/well
in 24-well plates and cultured in serum-supplemented medium for 48 h.
The cells were then washed two times with serum-free RPMI (no phenol
red) containing 300 
 
m
 
g/ml glutamine, 5 
 
m
 
g/ml transferrin, and 38 nM sele-
nium and cultured in the same medium supplemented with DIP–uPA (5
nM), uPA–PAI-1 complex (5 nM), PAI-1 (5 nM), or vehicle. After 30 h,
the cells were pulse-exposed to [
 
3
 
H]thymidine (1 
 
m
 
Ci/ml) for 1 h at 37
 
8
 
C
and washed two times with Earle’s balanced salt solution, 25 mM Hepes,
pH 7.4. The cultures were then incubated with 10% trichloroacetic acid
for 10 min at 4
 
8
 
C followed by a second incubation for 10 min at 22
 
8
 
C. Cell-
associated radioactivity was recovered by incubation in 1.0 M NaOH for
12 h. The pH was neutralized with 1.0 M HCl, and the cell extracts were
combined with Ready-Safe scintillation fluid (Beckman Coulter) for
counting in a Beckman Coulter scintillation counter.
The effects of uPA–PAI-1 complex on total viable cell number was as-
sessed in cultures of MCF-7, HT 1080, and 
 
b
 
3 integrin overexpressing
MCF-7 cells by 3-[4,5 dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bro-
mide (MTT) assay using the Cell Proliferation Kit I (Boehringer). MTT
measures the activity of the mitochondrial enzyme, succinyl dehydroge-
nase, which is expressed only in living cells and is not subject to regulation
(Mosmann, 1983). MCF-7 cells and 
 
b
 
3 integrin overexpressing MCF-7
cells (5 
 
3
 
 10
 
3
 
) were cultured in 96-well plates in serum-supplemented me-
dium for 48 h, washed two times, and treated with DIP–uPA (5 nM),
uPA–PAI-1 complex (5 nM), or PAI-1 (5 nM) in serum-free RPMI (no
phenol red) containing 300 
 
m
 
g/ml glutamine, 5 
 
m
 
g/ml transferrin, and 38
nM selenium. Some cultures were simultaneously treated with PD098059
(50 
 
m
 
M), or ML-7 (3 
 
m
 
M). After culturing for an additional 36 h, MTT as-
says were performed. Experiments with HT 1080 cells were performed
identically except that incubations with DIP–uPA and uPA–PAI-1 com-
plex were performed in serum-free MEM.
 
Results
 
uPA–PAI-1 Complex Activates ERK in a
uPAR-dependent Manner
 
We demonstrated previously that ERK1 and ERK2 are
rapidly phosphorylated and activated in uPA-treated
MCF-7 cells (Nguyen et al., 1998, 1999). The response re-
Figure 1. Activation of ERK1 and ERK2 in uPA–PAI-1 com-
plex-treated MCF-7 cells. MCF-7 cells were serum starved for 12 h
and then treated with 5 nM DIP–uPA (A), 5 nM uPA–PAI-1
complex (B), or vehicle (Control; A and B) for the indicated
times. (C) Cultures were incubated with uPA- or uPAR-specific
antibodies (1) or vehicle (2) for 15 min at 378C and then ex-
posed to uPA–PAI-1 complex (5 nM) or vehicle for 5 min. Phos-
phorylated ERK1 and ERK2 were detected by immunoblot anal-
ysis. The nitrocellulose membranes were then stripped and
reprobed with a separate antibody that detects total ERK. 
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quires uPA binding to uPAR and is highly transient since
levels of phosphorylated ERK return to baseline in 
 
,
 
5
min (Nguyen et al., 1998). In the present study, we con-
firmed our previous results, demonstrating rapid but tran-
sient ERK phosphorylation in MCF-7 cells treated with 5
nM DIP–uPA (Fig. 1 A). ERK phosphorylation was not
observed in MCF-7 cells that were treated with free PAI-1
(5 nM) in its active conformation (results not shown).
When two-chain uPA was incubated with an equimolar
concentration of PAI-1, stoichiometric uPA inactivation
was demonstrated by chromogenic substrate hydrolysis.
Preformed uPA–PAI-1 complex was immediately added to
MCF-7 cell cultures, and ERK phosphorylation was moni-
tored as a function of time. As was the case with free uPA,
uPA–PAI-1 complex (5 nM) induced rapid ERK phosphor-
ylation. However, the response to uPA–PAI-1 complex
was sustained throughout the course of the 30-min incuba-
tion (Fig. 1 B). Equivalent results were obtained when the
concentration of uPA–PAI-1 complex was decreased to 1.0
or 0.2 nM (results not shown). These experiments demon-
strate that PAI-1 does not directly activate ERK in MCF-7
cells but instead alters the kinetics of ERK phosphoryla-
tion/dephosphorylation in response to uPA.
uPA–PAI-1 complex binds with high affinity to two sep-
arate receptors in MCF-7 cells, uPAR and the VLDLr
(Cubellis et al., 1989; Jensen et al., 1990; Argraves et al.,
1995; Heegaard et al., 1995). MCF-7 cells express 
 
z
 
4,000
copies of uPAR/cell (Nguyen et al., 1998) and 
 
$
 
60,000
copies of the VLDLr/cell (Webb et al., 1999). To deter-
mine whether ERK activation by uPA–PAI-1 complex re-
quires uPAR, MCF-7 cells were treated for 15 min with
uPA- or uPAR-specific antibodies (25 
 
m
 
g/ml) that block
uPA binding to uPAR and then with uPA–PAI-1 complex.
As shown in Fig. 1 C, both antibodies blocked ERK phos-
phorylation in response to uPA–PAI-1 complex, whereas
nonimmune IgG (25 
 
m
 
g/ml) had no effect (results not
shown). These results demonstrate that binding of uPA–
PAI-1 complex to uPAR is necessary for ERK activation.
tPA binding to PAI-1 exposes the VLDLr recognition
site in PAI-1 analogously to uPA. However, tPA–PAI-1
complex does not associate with uPAR (Kasza et al.,
1997). To further test the role of uPAR in the activation of
ERK by uPA–PAI-1 complex, we compared the activity of
purified tPA–PAI-1 complex. In two separate experi-
ments, 5 nM tPA–PAI-1 complex failed to induce ERK
phosphorylation in MCF-7 cells (results not shown). These
results support our conclusion that uPAR ligation is neces-
sary for ERK activation by uPA–PAI-1 complex.
In MCF-7 cells, FAK, Shc, and Ras serve as necessary
upstream components in the pathway by which uPA bind-
ing to uPAR leads to ERK phosphorylation (Nguyen et
al., 1999, 2000). FAK phosphorylation also results from
uPA treatment of uPAR-expressing LNCap cells and en-
Figure 2. Tyrosine phosphorylation of FAK and Shc in uPA–
PAI-1 complex-treated MCF-7 cells. MCF-7 cells were trans-
fected to express FLAG-tagged FAK or HA-tagged Shc. The
cultures were then serum starved for 4 h and stimulated with
uPA–PAI-1 complex (5 nM) for the indicated times at 378C. Con-
trol cells were not treated with uPA–PAI-1 complex. FLAG-
tagged FAK was immunoprecipitated with FLAG-specific
monoclonal antibody, and Shc was immunoprecipitated with
HA-specific antibody 12CA5. Phosphorylated FAK and Shc
were detected by immunoblot analysis using phosphotyrosine-
specific antibody (P-tyr). Total levels of FAK and Shc were de-
tected by immunoblot analysis using FLAG-specific antibody
and Shc-specific antibody, respectively.
Figure 3. RAP blocks the sustained phosphorylation of ERK1
and ERK2 in uPA–PAI-1 complex-treated cells. (A) Serum-
starved MCF-7 cells were incubated with GST-RAP (0.4 mM) for
15 min at 378C. Cultures were then treated with 5 nM uPA–PAI-1
complex for the indicated times. Control cells were not treated
with RAP or uPA–PAI-1 complex. (B) MCF-7 cells were serum
starved and then treated with GST-RAP (1) for the indicated
times at 378C. Cultures were also incubated with GST-RAP (1)
or vehicle (2) for 15 min at 378C and then treated with EGF for 5
min at 378C. Control cells were not treated with RAP or EGF.
Phosphorylated and total ERK1 and ERK2 were detected by im-
munoblot analysis. 
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dothelial cells (Tang et al., 1998; Yebra et al., 1999). To de-
termine whether the pathways that link uPA and uPA–
PAI-1 complex to ERK involve the same upstream fac-
tors, we examined the phosphorylation of FAK and Shc in
uPA–PAI-1 complex-treated MCF-7 cells. As shown in
Fig. 2, FAK and Shc were tyrosine phosphorylated when
MCF-7 cells were treated with 5 nM uPA–PAI-1 complex.
Both responses were sustained for at least 30 min.
 
Sustained ERK Activation by uPA–PAI-1 Complex 
Requires the VLDLr
 
Free and uPAR-associated uPA–PAI-1 complex both
bind to the VLDLr (Argraves et al., 1995; Conese et al.,
1995; Heegaard et al., 1995; Webb et al., 1999). To deter-
mine whether the VLDLr is required for ERK activation
by uPA–PAI-1 complex, MCF-7 cells were treated with 5
nM uPA–PAI-1 complex in the presence of RAP. RAP
binds to LDL receptor homologues, including the VLDLr
and inhibits the binding of all other known ligands, includ-
ing uPA–PAI-1 complex (Battey et al., 1994; Argraves et
al., 1995; Heegaard et al., 1995, Webb et al., 1999). As
shown in Fig. 3 A, uPA–PAI-1 complex induced ERK
phosphorylation in RAP-treated MCF-7 cells, suggesting
that the VLDLr is not required for this response. How-
ever, in the presence of RAP, ERK phosphorylation was
transient. Within 5 min, the level of phosphorylated ERK
returned to baseline, mimicking the kinetics observed with
DIP–uPA. RAP did not promote ERK phosphorylation in
the absence of uPA–PAI-1 complex or inhibit ERK phos-
phorylation in response to EGF (Fig. 3 B). These results
are consistent with a model in which uPAR is necessary
for ERK phosphorylation by uPA–PAI-1 complex and the
VLDLr is necessary for sustaining the response.
To further test the role of the VLDLr in uPA–PAI-1 com-
plex-promoted ERK phosphorylation, uPA–PAI-1 complex
was prepared using a mutant form of PAI-1 (PAI-1
 
R76E
 
)
that binds to LDL receptor homologues with greatly de-
creased affinity (Stefansson et al., 1998). uPA–PAI-1
 
R76E
 
complex (5 nM) induced ERK phosphorylation in MCF-7
cells. However, the response was transient (Fig. 4). These
results support the conclusion that cooperation between
uPAR and the VLDLr is necessary for sustained ERK
phosphorylation in MCF-7 cells.
 
Sos Association with Shc Is Sustained in uPA–PAI-1 
Complex-treated Cells
 
The Ras–ERK signaling pathway includes negative feed-
back loops that may be responsible for transient ERK acti-
vation. An example is the MEK-dependent phosphoryla-
tion of Sos, which promotes dissociation of Sos from Grb2
(Langlois et al., 1995). When MCF-7 cells are stimulated
with uPA, Sos initially coimmunoprecipitates with Shc,
probably reflecting the formation of Shc–Grb2–Sos com-
plex. However, by 10 min, the complex is no longer ob-
served even though Shc remains tyrosine phosphorylated
(Nguyen et al., 2000). Sos dissociation from Grb2 and Shc
may functionally dissociate Ras from upstream activators.
Sos1 coimmunoprecipitated with Shc in MCF-7 cells
that were treated with uPA–PAI-1 complex (Fig. 5) as was
previously observed with uPA (Nguyen et al., 2000). How-
ever, in the uPA–PAI-1 complex-treated cells, Sos1 re-
mained associated with Shc for at least 30 min (the last
time point in the experiment, 
 
n 
 
5 
 
3). When MCF-7 cells
were treated with RAP to block the function of the
VLDLr and then with uPA–PAI-1 complex, Sos1 still as-
sociated with Shc. However, by 10 min, the complex was
no longer observed. Thus, sustained ERK phosphoryla-
tion in uPA–PAI-1 complex-treated MCF-7 cells corre-
Figure 4. uPA–PAI-1 complex formed with a mutant form of
PAI-1 that binds with greatly decreased affinity to the VLDLr in-
duces transient ERK phosphorylation. MCF-7 cells were cul-
tured in serum-free medium for 12 h and then exposed to 5 nM
uPA–PAI-1R76E complex for the indicated times. Control cells
were not incubated with uPA–PAI-1R76E complex. Phosphory-
lated and total ERK1 and ERK2 were detected by immunoblot
analysis.
Figure 5. Association of Sos with Shc is sustained in uPA–PAI-1
complex-treated cells. MCF-7 cells were incubated in serum-free
medium for 12 h. The cells were then treated with 5 nM uPA–
PAI-1 complex for the indicated times (top panel). Some cultures
were treated with GST-RAP for 15 min and then with vehicle for
1 min or with uPA–PAI-1 complex for the indicated times (bot-
tom panel). Shc was isolated by immunoprecipitation. The immu-
noprecipitates were then subjected to immunoblot analysis to de-
tect Sos1. Control cells were not treated with uPA–PAI-1
complex or RAP. 
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lates with the continued presence of Shc–Grb2–Sos com-
plex and requires the VLDLr.
 
Sustained ERK Phosphorylation Requires the 
Continuous Presence of uPA–PAI-1 Complex
 
The VLDLr plays a critical role in cell signaling initiated
by the extracellular matrix protein, reelin (D’Arcangelo et
al., 1999; Hiesberger et al., 1999). This activity may be ex-
plained by the ability of reelin to bind simultaneously to
the VLDLr and to a separate coreceptor with tyrosine ki-
nase activity so that an intracellular kinase is brought into
close juxtaposition with a VLDLr-associated substrate
such as disabled 1 (Hiesberger et al., 1999). Similarly,
uPA–PAI-1 complex may induce sustained ERK phos-
phorylation by a “receptor-bridging” mechanism.
A second model to explain the sustained activation of
ERK in uPA–PAI-1 complex-treated MCF-7 cells in-
volves the ability of the VLDLr to mediate uPAR endocy-
tosis and recycling when uPA–PAI-1 complex binds to
uPAR (Conese et al., 1995; Nykjær et al., 1997; Webb et
al., 1999). Because uPA-initiated ERK activation in MCF-7
cells is transient, due to processes such as Shc–Grb2–Sos
dissociation, uPAR endocytosis and recycling may provide
a constant pool of unliganded uPAR to initiate new signal-
ing events. If this model is correct, then a continuous
source of free uPA–PAI complex should be necessary to
sustain ERK phosphorylation. To test this hypothesis,
MCF-7 cells were pulse-exposed to 5 nM uPA–PAI-1
complex for 1 min, washed, and then incubated in fresh
medium without uPA–PAI-1 complex. As shown in Fig. 6,
ERK was phosphorylated in the early time points. How-
ever, by 15 min, the level of phosphorylated ERK re-
turned to baseline. Thus, a continuous source of free
uPA–PAI-1 complex is necessary to sustain ERK phos-
phorylation in MCF-7 cells.
 
uPA–PAI-1 Complex Promotes MCF-7 Cell Migration
 
uPA promotes cell migration by a mechanism that re-
quires ERK activation in parental MCF-7 cells, HT 1080
cells, and in MCF-7 cells that are transfected to overex-
press uPAR (Nguyen et al., 1998, 1999). In the present
study, Transwell membranes were coated on the underside
surface with FBS to form a haptotactic vitronectin gradi-
ent (Hayman et al., 1985; Nguyen et al., 1998). DIP–uPA,
PAI-1, or uPA–PAI-1 complex (each at 1 nM) was added
to both Transwell chambers, and migration was allowed to
proceed for 6 h. As shown in Fig. 7 A, DIP–uPA and
uPA–PAI-1 complex promoted MCF-7 cell migration
equivalently, whereas free PAI-1 had no effect. In control
experiments, we demonstrated that neither DIP–uPA or
uPA–PAI-1 complex affect MCF-7 cell growth (MTT as-
say) in the time frame of the migration experiments (6 h).
In other studies that are not shown, we demonstrated that
uPA–PAI-1 complex and DIP–uPA promote MCF-7 cell
migration equivalently when both Transwell membrane
surfaces are coated with FBS and migration is allowed to
proceed for 24 h. However, due to the longer incubation
Figure 6. Sustained ERK phosphorylation requires the continu-
ous presence of uPA–PAI-1 complex. MCF-7 cells were serum
starved for 12 h and then pulse-exposed to 5 nM uPA–PAI-1
complex for 1 min at 378C. Cultures were then processed for ERK
analysis (1 min) or washed and incubated in fresh medium with-
out uPA–PAI-1 complex for the indicated times. Control cells
were not treated with uPA–PAI-1 complex. Phosphorylated and
total ERK1 and ERK2 were detected by immunoblot analysis.
Figure 7. uPA–PAI-1 complex promotes MCF-7 cell migration. (A)
MCF-7 cells were treated with DIP–uPA, uPA–PAI-1 complex,
PAI-1, or vehicle (“C”) for 15 min and then added to Transwells in
the presence of the same proteins or complexes. The cells were al-
lowed to migrate for 6 h. (B) Transwell membranes were coated
with FBS and then preincubated with the indicated concentrations
of PAI-1 for 15 min before adding cells to the upper chamber. 
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time, we cannot rule out the possibility that cell prolifera-
tion affected these results.
Previous studies have demonstrated that PAI-1 regu-
lates cell migration on vitronectin; however, high concen-
trations of PAI-1 may be necessary (Stefansson and
Lawrence, 1996; Kjøller et al., 1997; Waltz et al., 1997).
Furthermore, the function of PAI-1 in cell migration may
depend on whether 
 
a
 
V
 
 integrins or uPAR function as the
primary adhesion receptor (Deng et al., 1996; Stefansson
and Lawrence, 1996; Kjøller et al., 1997; Waltz et al.,
1997). To understand more fully the role of free PAI-1 in
the regulation of MCF-7 cell migration, we studied in-
creasing concentrations of PAI-1. As shown in Fig. 7 B,
MCF-7 cell migration was significantly inhibited when the
Transwell membranes were preincubated for 15 min with
10–500 nM PAI-1 (
 
p 
 
, 
 
0.01). However, when the PAI-1
was added to the Transwell chambers simultaneously with
the cells, migration was not affected (results not shown).
We interpret these results to indicate that PAI-1 inhibits
MCF-7 cell migration by binding to the immobilized vi-
tronectin and blocking cell adhesion (Stefansson and
Lawrence, 1996).
 
uPA–PAI-1 Complex Promotes MCF-7 Cell Growth
 
The length of time that ERK phosphorylation is sustained
may determine whether active ERK translocates to the
nucleus and promotes cell growth (Lenormand et al.,
1993). We demonstrated previously that uPA does not
stimulate MCF-7 cell proliferation (Nguyen et al., 1998).
To determine whether uPA–PAI-1 complex functions as a
mitogen, [
 
3
 
H]thymidine incorporation experiments were
conducted. Fig. 8 A shows that [
 
3
 
H]thymidine incorpora-
tion was increased 3.5 
 
6 
 
0.2-fold (
 
n 
 
5 
 
4) in MCF-7 cells
that were exposed to 5 nM uPA–PAI-1 complex for 30 h.
Under equivalent conditions, DIP–uPA and free PAI-1
had no effect on [
 
3
 
H]thymidine incorporation.
We also assessed the effects of uPA–PAI-1 complex on
MCF-7 cell growth using the MTT assay, which measures
total viable cell number (Fig. 8 B). MCF-7 cells that were
incubated for 36 h in serum free–defined medium (control
cells) demonstrated a 48 
 
6 
 
7% increase in cell number,
which was arbitrarily designated 100% growth. DIP–uPA
(5 nM) did not cause a statistically significant increase
in cell growth compared with the control. Similarly, free
PAI-1 (5 nM) had no effect on cell growth. However, when
uPA–PAI-1 complex was added, cell growth increased
3.0 
 
6 
 
0.1-fold compared with the control, corresponding to
 
z
 
1.25 doublings in 36 h. The increase in growth measured
by the MTT assay may reflect an increased rate of cell pro-
liferation and/or a decreased rate of apoptosis.
To determine whether activated ERK is required for
uPA–PAI-1 complex-induced MCF-7 cell growth, the
MEK antagonist, PD098059 (50 
 
m
 
M), was added. In four
separate experiments, PD098059 did not significantly af-
fect MCF-7 cell growth in serum free–defined medium or
in medium supplemented with DIP–uPA. However,
PD098059 completely blocked the response to uPA–PAI-1
complex (results not shown). Interestingly, the MLCK in-
hibitor, ML-7 (3 
 
m
 
M), had no effect on the response to
uPA–PAI-1 complex. In the presence of ML-7, uPA–PAI-1
complex increased cell growth 2.9 6 0.2-fold compared
with the control, which was not significantly different than
that observed with uPA–PAI-1 complex alone. The same
concentration of ML-7 completely blocked uPA-promoted
MCF-7 cell migration (Nguyen et al., 1999).
The VLDLr Is Required for uPA–PAI-1
Complex-induced MCF-7 Cell Growth
We hypothesized that uPA–PAI-1 complex induces cell
growth based on its ability to sustain ERK phosphoryla-
tion, which is dependent on cooperation between uPAR
and the VLDLr. To test this hypothesis, we studied the ef-
fects of uPA–PAI-1R76E complex on cell growth. uPA–
Figure 8. uPA–PAI-1 complex promotes MCF-7 cell growth. (A)
MCF-7 cells were cultured in serum-supplemented medium for
48 h. The cells were then washed and cultured in serum-free me-
dium supplemented with DIP–uPA, uPA–PAI-1 complex, PAI-1,
or vehicle (“C”). After 30 h, the cells were pulse-exposed to
[3H]thymidine for 1 h at 378C. The cells were then washed and in-
cubated with 10% trichloroacetic acid. Cell-associated radioac-
tivity was recovered in 1 M NaOH. (B) MCF-7 cells were cul-
tured in serum-supplemented medium for 48 h, washed, and
treated with uPA, uPA–PAI-1 complex, PAI-1, uPA–PAI-1R76E
complex, or vehicle (“C”) in serum free–defined medium. After
culturing for an additional 36 h, MTT assays were performed.
The graph shows the increase in cell number relative to the in-
crease observed in control cultures. (C) MCF-7 cells were pulse-
exposed to uPA–PAI-1 complex for 4 h, in the presence or ab-
sence of RAP. After culturing for an additional 32 h, cell growth
was determined by MTT assay.The Journal of Cell Biology, Volume 152, 2001 748
PAI-1R76E complex does not bind to the VLDLr (Stefans-
son et al., 1998) and elicits highly transient ERK phosphor-
ylation. As shown in Fig. 8 B, uPA–PAI-1R76E complex
failed to promote MCF-7 cell growth compared with the
control, supporting our model.
To further test our hypothesis regarding the function of
the VLDLr in uPA–PAI-1 complex-promoted MCF-7 cell
growth, we examined the effects of RAP. When cells are
cultured in the presence of RAP for long periods of time
(1–5 d), uPAR endocytosis is inhibited and cell-surface
uPAR levels slowly increase (Conese et al., 1995; Weaver
et al., 1997; Webb et al., 1999). To avoid this complication,
we executed a pulse-exposure protocol. MCF-7 cells were
pretreated with 0.4 mM RAP or vehicle for 15 min and
then with uPA–PAI-1 complex in the presence or absence
of RAP for 4 h. The cells were then washed and incubated
in serum free–defined medium in the absence of RAP and
uPA–PAI-1 complex for an additional 32 h. Total cell
number was determined by MTT assay. As shown in Fig. 8
C, pulse exposure of MCF-7 cells to RAP for 4.25 h did
not affect cell growth. By contrast, a 3.2 6 0.5-fold in-
crease in cell growth was observed when MCF-7 cells were
pulse-exposed to uPA–PAI-1 complex. This result sug-
gests that the growth-promoting activity of uPA–PAI-1
complex is sustained even after the complex is removed.
RAP blocked the growth-promoting activity of uPA–PAI-1
complex, again supporting our model in which the VLDLr
and sustained ERK phosphorylation are required for cell
growth in response to uPAR ligation.
uPAR-promoted Cell Growth Correlates with the 
Duration of ERK Phosphorylation
HT 1080 cells demonstrate increased migration when
treated with DIP–uPA, and the response is completely
blocked by PD098059 (Nguyen et al., 1999). Although HT
1080 cells express significant amounts of uPA (Tsuboi and
Rifkin, 1990; Laug et al., 1992), we demonstrated previ-
ously that under our culturing conditions, the amount of
endogenously produced uPA is sufficient to saturate ,5%
of the available uPAR, accounting for the ability of these
cells to respond to exogenously added uPA (Nguyen et al.,
1999; Webb et al., 2000).
Fig. 9 A shows that ERK was phosphorylated in HT 1080
cells that were treated with 10 nM DIP–uPA. ERK phos-
phorylation was observed within 1 min. However, the re-
sponse was sustained for at least 30 min. DIP–uPA also in-
duced HT 1080 cell growth (Fig. 9 B). The magnitude of the
response was comparable with that observed using an equal
concentration of uPA–PAI-1 complex. PD098059 inhibited
the growth-promoting activity of DIP–uPA and uPA–PAI-1
complex without affecting basal HT 1080 cell growth, indi-
cating an essential role for activated ERK.
b3 integrin expression sustains ERK phosphorylation in
response to a number of agonists in cells that express aVb5
(Elicieri et al., 1998; Nguyen et al., 1999). The reason for
this remains unclear. In MCF-7 cells that are transfected to
overexpress b3 and treated with DIP–uPA (10 nM), ERK
phosphorylation is observed within 1 min and remains ele-
vated for at least 40 min (Nguyen et al., 1999). As shown in
Figure 9. uPA stimulates sustained ERK phosphorylation and
growth in HT 1080 cells. (A) HT 1080 cells were serum starved
for 12 h and then treated with 10 nM DIP–uPA for the indicated
times. Cell extracts were isolated and subjected to immunoblot
analysis to detect phosphorylated and total ERK. Control cells
were not treated with DIP–uPA. (B) HT 1080 cells were treated
with DIP–uPA or uPA–PAI-1 complex in serum-free medium
for 36 h. Some cultures were treated with PD098059. Cell growth
was determined by MTT assay. The increase in cell number is
standardized against that observed in control cultures.
Figure 10. uPA stimulates growth in b3 integrin overexpressing
MCF-7 cells. (A) aVb3 expression was demonstrated in b3 inte-
grin overexpressing MCF-7 cells by FACS® analysis. (B) These
cells were treated with DIP–uPA or uPA–PAI-1 complex for 36
h in the presence and absence of PD098059. Cell growth was de-
termined by MTT assay. The increase in cell number is plotted
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Fig. 10 A, MCF-7 cells that were transfected to overex-
press b3 and single-cell cloned, expressed cell-surface
aVb3 as determined by FACS analysis with antibody
LM609.  b3 overexpressing MCF-7 cells also demonstrated
increased growth when treated with DIP–uPA or uPA–
PAI-1 complex (Fig. 10 B). Identical results were obtained
with a second distinct b3 overexpressing clone (results
not shown). When b3 overexpressing MCF-7 cells were
treated with uPA or uPA–PAI-1 complex in the presence
of PD098059, the increase in cell growth was blocked.
Discussion
The Ras–ERK signaling pathway regulates diverse cellu-
lar processes, including proliferation, differentiation, ap-
optosis, and migration. Whether activated ERK stimulates
cell growth may depend on a number of factors, including
the duration of the response (Meloche et al., 1992; Lenor-
mand et al., 1993; Sergeant et al., 2000). We demonstrated
previously that uPA activates ERK in MCF-7 cells without
promoting cell growth, probably reflecting the highly tran-
sient nature of the signaling response (Nguyen et al., 1998,
1999). We now demonstrate that free PAI-1 does not inde-
pendently activate ERK but instead modifies the response
obtained when uPA ligates uPAR so that ERK phosphor-
ylation is sustained. In MCF-7 cells, sustained ERK phos-
phorylation is necessary to convert uPA into a mitogen.
The ability of uPA–PAI-1 complex to induce sustained
ERK phosphorylation in MCF-7 cells requires the recruit-
ment of uPAR and the VLDLr, which function coopera-
tively. All of our evidence suggests that cell signaling is ini-
tiated when uPA–PAI-1 complex binds to uPAR and
follows a pathway that involves FAK and Shc as was de-
scribed previously for uPA (Nguyen et al., 2000). The
function of the VLDLr in uPA–PAI-1 complex-promoted
ERK activation is to sustain the response, probably by en-
gaging uPA–PAI-1 complex after it has bound uPAR. The
MCF-7 cell provided an excellent model system to demon-
strate cooperativity between uPAR and the VLDLr given
the highly transient nature of uPA-induced ERK phos-
phorylation in this cell line. In HT 1080 cells and MCF-7
cells that overexpress b3 integrin, uPA induced more sus-
tained ERK phosphorylation and, as a result, functioned
comparably to uPA–PAI-1 complex in cell growth assays.
The possibility that PAI-1, the VLDLr, and uPAR co-
operate to convert uPA into a cancer cell mitogen in vivo
represents an appealing model to explain why PAI-1 ex-
pression adversely affects breast cancer progression. All of
the components of uPA–uPAR system have been identi-
fied in breast cancer. The malignant epithelial cells in
breast cancers express variable amounts of uPAR. How-
ever, uPAR is almost always detectable, at least at the
level of mRNA (Jankun et al., 1993; Hildenbrand et al.,
1998). Furthermore, malignant breast epithelia tend to be
strongly immunoreactive for the VLDLr (Martensen et
al., 1997). uPA is expressed at high levels by benign cells
that are intermixed with malignant epithelia in breast can-
cers, establishing the context for a paracrine interaction
(Nielsen et al., 1996). We propose that uPA–PAI-1 com-
plex may promote growth of malignant cells in some
breast cancers, whereas uPA does not as was observed in
MCF-7 cells. To explore the feasibility of this argument, it
will be important to gain a better understanding of the fac-
tors that control the kinetics of ERK phosphorylation and
dephosphorylation in breast cancer cells and in other cells
in general. The results reported here suggest that stability
of Shc–Grb2–Sos complex is a key determinant of whether
ERK phosphorylation is sustained in MCF-7 cells. Other
pathways, including those that lead to the activation of dual
specificity phosphatases, may also be involved (Keyse,
1995).
The mitogenic activity of uPA–PAI-1 complex towards
MCF-7 cells, b3 integrin overexpressing MCF-7 cells, and
HT 1080 cells and the mitogenic activity of DIP–uPA to-
wards the latter two cell lines was completely blocked by
the MEK antagonist, PD098059, supporting an essential
role for the Ras–ERK pathway in uPA promoted cell pro-
liferation. In other cell types, blocking the activity of
casein kinase 2 completely neutralizes the mitogenic activ-
ity of uPA (Dumler et al., 1999). Although it is possible
that separate signaling pathways are operational in differ-
ent cell types, we think it is much more likely that uPAR
ligation triggers signaling through distinct but cooperative
pathways that must be simultaneously activated in order
to observe cell growth. According to this model, inhibiting
either casein kinase 2 or ERK would be expected to inde-
pendently inhibit mitogenesis.
Once activated, ERK translocates to multiple subcellu-
lar compartments, including the nucleus, the cytoskeleton,
the plasma membrane, and newly formed focal adhesions
(Chen et al., 1992; Gonzalez et al., 1993; Lenormand et al.,
1993; Reszka et al., 1995; Fincham et al., 2000). Failure of
ERK to translocate to the nucleus may partially explain
why transient ERK phosphorylation in MCF-7 cells does
not stimulate cell growth (Meloche et al., 1992; Lenor-
mand et al., 1993; Sergeant et al., 2000). By contrast,
MLCK is activated by ERK or an ERK-dependent kinase
rapidly and effectively in DIP–uPA-treated MCF-7 cells,
and this reaction appears to be responsible for the stimula-
tion of cell migration (Nguyen et al., 1999). MLCK re-
mains phosphorylated, and levels of serine-phosphory-
lated myosin II regulatory light chain remain elevated long
after the level of phosphorylated ERK returns to baseline
(Nguyen et al., 1999). Rapid and sustained activation of
MLCK explains why DIP–uPA and uPA–PAI-1 complex
are comparable promoters of MCF-7 cell migration.
An NPXY motif in the cytoplasmic tail of the VLDLr
binds adaptor proteins, such as disabled 1, that function in
cell signaling (Trommsdorff et al., 1998; Hiesberger et al.,
1999). By bridging the VLDLr and uPAR, uPA–PAI-1
complex brings the intracytoplasmic tail of the VLDLr
into close proximity with the uPAR-associated signaling
machinery and may thereby alter the character of the sig-
naling response induced by uPAR ligation. An alternative
model to explain the function of PAI-1 as a uPA response
modifier involves the ability of the VLDLr to mediate
uPAR internalization in association with uPA–PAI-1
complex (Webb et al., 1999). In this model, each cell-sig-
naling event is viewed as highly transient, perhaps due to
the instability of Shc–Grb2–Sos complex in uPA-treated
MCF-7 cells. Clearance of uPA–PAI-1–uPAR complex
from the cell surface may allow for the formation of new
multicomponent signaling receptors in which unliganded
uPAR associates with adaptor proteins that are available
in short supply. Binding of uPA–PAI-1 complex to each
newly formed receptor complex induces transient ERKThe Journal of Cell Biology, Volume 152, 2001 750
activation. However, due to uPAR endocytosis and the
continuous reformation of signaling–receptor complexes,
the integrated response to uPA–PAI-1 complex is suffi-
cient to maintain a stable pool of Shc–Grb2–Sos complex
and ERK at an increased level of phosphorylation. In sup-
port of this model, a continuous source of free uPA–PAI-1
complex was necessary for sustained ERK phosphoryla-
tion in MCF-7 cells. The uPAR that enters into newly
formed signaling–receptor complexes may be derived
from distinct plasma membrane microdomains, intracyto-
plasmic vesicles, and/or recycling pools.
Based on this and previous studies, PAI-1 emerges as a
complex regulator of the uPA–uPAR system. By binding
directly to vitronectin, PAI-1 may alter cell adhesion and
migration (Deng et al., 1996; Stefansson and Lawrence,
1996; Kjøller et al., 1997; Waltz et al., 1997). By binding
uPAR-associated two-chain uPA, PAI-1 inhibits activa-
tion of the cell surface proteinase cascade and may
thereby inhibit cellular penetration of tissue boundaries.
As a result of the same reaction, PAI-1 promotes uPAR
endocytosis by a mechanism that depends on uPAR bridg-
ing to LDL receptor homologues (Conese et al., 1995;
Nykjær et al., 1997; Webb et al., 1999). Since the recycling
efficiency of uPAR is ,100%, continuous uPA–PAI-1
complex-promoted uPAR endocytosis results in the re-
equilibration of cell surface uPAR levels below that ob-
served in the absence of LDL receptor homologues
(Weaver et al., 1997; Webb et al., 1999, 2000). However,
this reequilibration occurs very slowly. In a more rapid
time frame, uPA–PAI-1 complex may alter the character
of uPAR initiated cell signaling compared with free uPA.
By sustaining the activity of the Ras–ERK pathway, PAI-1
may promote cell growth and potentially alter other physi-
ologic processes such as apoptosis. The ability of PAI-1 to
modulate uPAR-initiated cell signaling represents a novel
mechanism whereby PAI-1 may influence cancer progres-
sion in vivo.
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